Raymond James & Associates Lexicon Pharmaceuticals, Inc. Call Options Transaction History
Raymond James & Associates
- $146 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LXRX
# of Institutions
122Shares Held
159MCall Options Held
2.11MPut Options Held
412K-
Artal Group S.A. Luxembourg, N4118MShares$195 Million15.21% of portfolio
-
Black Rock Inc. New York, NY7.69MShares$12.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.4MShares$10.6 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.54MShares$5.88 Million0.19% of portfolio
-
Geode Capital Management, LLC Boston, MA2.39MShares$3.97 Million0.0% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $313M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...